T Man Pharmaceutical PCL vs Guobang Pharma: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

T Man Pharmaceutical PCL (TMAN.BK)

Q3 202622 Jul – 8 Oct 2026

▲3

Longevity New S-Curve and 4bn baht target TMAN set a goal of 4 billion baht revenue in 3-5 years (from 2.5 billion in 2025), adding a longevity supplement business with 15-20 new products a year and a new own brand. This gives investors a bigger growth story, which supports the share price.
It is the main new strategic plan that reframes TMAN's growth outlook.
Propoliz pushed to regional and global brand TMAN is expanding Propoliz beyond 7 countries to 10+, with South Korea and Indonesia distributor deals and first Korea shipment in October, plus a celebrity 'Friends of Propoliz' campaign. More export markets and marketing mean more sales, lifting profit expectations.
Export expansion and marketing are concrete new demand drivers for the key brand.
Hospital channel and OEM growth TMAN plans to raise hospital channel revenue share to 15-20% from 10%, and its OEM contract manufacturing has grown over 100%, recently adding a major customer. Higher-margin channels and bigger OEM orders support revenue and profit recovery.
It shows where near-term growth is coming from beyond the pharmacy slump.
Weak first-half profit but recovery expected First-half net profit fell 7.2% to 212 million baht on higher marketing and tax costs, even as revenue rose 8.2%. Management and brokers still expect a strong second-half recovery, so the weak result is a real counterweight but seen as temporary.
It is the key negative fact readers must weigh against the growth plans.

August 202622 Jul – 8 Oct 2026

▲3

Longevity New S-Curve and 4bn baht target TMAN set a goal of 4 billion baht revenue in 3-5 years (from 2.5 billion in 2025), adding a longevity supplement business with 15-20 new products a year and a new own brand. This gives investors a bigger growth story, which supports the share price.
It is the main new strategic plan that reframes TMAN's growth outlook.
Propoliz pushed to regional and global brand TMAN is expanding Propoliz beyond 7 countries to 10+, with South Korea and Indonesia distributor deals and first Korea shipment in October, plus a celebrity 'Friends of Propoliz' campaign. More export markets and marketing mean more sales, lifting profit expectations.
Export expansion and marketing are concrete new demand drivers for the key brand.
Hospital channel and OEM growth TMAN plans to raise hospital channel revenue share to 15-20% from 10%, and its OEM contract manufacturing has grown over 100%, recently adding a major customer. Higher-margin channels and bigger OEM orders support revenue and profit recovery.
It shows where near-term growth is coming from beyond the pharmacy slump.
Weak first-half profit but recovery expected First-half net profit fell 7.2% to 212 million baht on higher marketing and tax costs, even as revenue rose 8.2%. Management and brokers still expect a strong second-half recovery, so the weak result is a real counterweight but seen as temporary.
It is the key negative fact readers must weigh against the growth plans.

Latest22 Jul – 8 Oct 2026

▲3

Longevity New S-Curve and 4bn baht target TMAN set a goal of 4 billion baht revenue in 3-5 years (from 2.5 billion in 2025), adding a longevity supplement business with 15-20 new products a year and a new own brand. This gives investors a bigger growth story, which supports the share price.
It is the main new strategic plan that reframes TMAN's growth outlook.
Propoliz pushed to regional and global brand TMAN is expanding Propoliz beyond 7 countries to 10+, with South Korea and Indonesia distributor deals and first Korea shipment in October, plus a celebrity 'Friends of Propoliz' campaign. More export markets and marketing mean more sales, lifting profit expectations.
Export expansion and marketing are concrete new demand drivers for the key brand.
Hospital channel and OEM growth TMAN plans to raise hospital channel revenue share to 15-20% from 10%, and its OEM contract manufacturing has grown over 100%, recently adding a major customer. Higher-margin channels and bigger OEM orders support revenue and profit recovery.
It shows where near-term growth is coming from beyond the pharmacy slump.
Weak first-half profit but recovery expected First-half net profit fell 7.2% to 212 million baht on higher marketing and tax costs, even as revenue rose 8.2%. Management and brokers still expect a strong second-half recovery, so the weak result is a real counterweight but seen as temporary.
It is the key negative fact readers must weigh against the growth plans.